The Italian Coronary Artery Aneurysm and Ectasia In Patients With Acute Coronary Syndrome

ITAlian Coronary Artery Aneurysm and Ectasia Observational Study in Patients With Acute Coronary Syndrome: The ITACA Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05051917

Acronym

ITACA

Enrollment

500

Registered

2021-09-21

Start date

2021-09-01

Completion date

2026-09-01

Last updated

2024-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Angiographic Evidence if Coronary Aneurysms, Ectasia

Keywords

Aute Coronary Syndrome, Coronary Artery Artery, Ectasia

Brief summary

The ITACA study is a prospective, observational no profit registry enrolling patients with Acute Coronary Syndrome and angiographic evidence of coronary aneurysms and/or ectasia.

Detailed description

The ITACA study is aimed at evaluating short and long term outcomes in patients with acute coronary sindrome and angiographic evidence of coronary aneurysm and/or actasia. Data regarding safety and effectiveness of invasive and pharmacological treatment strategies will be also collected.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Signature of informed consent; * Patients aged ≥18 years; * diagnosis of ACS (ST-elevation myocardial infarction, non ST-elevation myocardial infarction, unstable angina), in accordance with the definition provided in the latest guidelines; * diagnosis of ectasia or coronary aneurysm according to the definitions contained in this protocol, either in the culprit vessel of the SCA than in another vessel. Coronary pseudoaneurysms are excluded.

Exclusion criteria

* impossibility or unwillingness to provide signed informed consent; * contraindications to dual antiplatelet therapy; * contraindications to anticoagulant therapy; * active bleeding or severe anemia (Hb \<6 g / dl); * life expectancy \<12 months; * female patients with potential pregnancy;

Design outcomes

Primary

Measure	Time frame	Description
Major adverse cardiac events	two years	A composite endpoint of myocardial infarction, stroke, cardiovascular death, myocardial revascularization and hospitalisation due to cardiovascular events

Countries

Italy

Outcome results